It’s been 8 and a half years since
Abbott Laboratories (NYSE:
ABT) spun off its branded drug unit into a publicly-traded company. At the time, AbbVie had annual revenue of $18.4 billion. Half of its annual sales came from Humira, the company’s biologic therapy intended to treat autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn’s disease and the like.
Today, ABBV has $45.8 billion in sales (2020) and $11.4 billion in operating earnings. Humira now accounts for 43% of its overall sales, down from 61% in 2018. AbbVie increased its quarterly dividend by 10.2% to $1.30 per share with its February dividend payment. An annualized dividend of $5.20 yields 4.5%.
China
Florida
United-states
James-robo
Steve-rendle
Brian-cornell
Hubert-joly
Hormel
Its-employer-services
Employer-services
Financial-services
Nextera-energy